To assess the risk of losing remission, low disease activity (LDA) or radiographic progression in the case of (1) discontinuing or (2) tapering doses of biological disease-modifying antirheumatic drugs (bDMARDs) compared with continuation of the initial treatment regimen in rheumatoid arthritis (RA) patients with remission or LDA.

Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis

Rossini, Maurizio;
2018-01-01

Abstract

To assess the risk of losing remission, low disease activity (LDA) or radiographic progression in the case of (1) discontinuing or (2) tapering doses of biological disease-modifying antirheumatic drugs (bDMARDs) compared with continuation of the initial treatment regimen in rheumatoid arthritis (RA) patients with remission or LDA.
das28; dmards (biologic); rheumatoid arthritis
File in questo prodotto:
File Dimensione Formato  
515.full.pdf

non disponibili

Tipologia: Documento in Post-print
Licenza: Accesso ristretto
Dimensione 643.86 kB
Formato Adobe PDF
643.86 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/971084
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 38
  • ???jsp.display-item.citation.isi??? 43
social impact